BriaCell Therapeutics Corp. (BCTX) 10-Year Financial Performance & Capital Metrics

BCTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutBriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.Show more

Revenue $0
EBITDA -$38M +17.3%
Net Income -$36M -457.4%
EPS (Diluted) -86.25 -44.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -363.04%
ROIC -1263.21%
Debt/Equity -
Interest Coverage -735.71

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 61.4% through buybacks
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-64.28%

EPS CAGR

10Y-

5Y-

3Y-

TTM62.75%

ROCE

10Y Avg-762.92%

5Y Avg-151.59%

3Y Avg-233.64%

Latest-341.62%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Jul 2016	Jul 2017	Jul 2018	Jul 2019	Jul 2020	Jul 2021	Jul 2022	Jul 2023	Jul 2024	Jul 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	1.8K	290	16.88K	18.83K	18.73K	19.46K	19.42K	20.51K	114.64K	147.89K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-1.8K	-289	-16.88K	-18.83K	-18.73K	-19.46K	-19.42K	-20.51K	-114.64K	-147.89K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-2.19%	0.84%	-57.4%	-0.12%	0.01%	-0.04%	0%	-0.06%	-4.59%	-0.29%
Operating Expenses+	2.19M	3.21M	4.96M	6.23M	4.82M	8.88M	19.42M	31.24M	45.43M	37.59M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	1.24M	1.09M	1.85M	1.29M	1.84M	6.3M	9.22M	10.64M	8.29M	5.93M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	952.15K	2.12M	3.11M	4.94M	2.98M	2.58M	10.2M	20.6M	37.14M	29.5M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	2.15M
Operating Income+	-2.19M	-3.21M	-4.97M	-6.25M	-4.84M	-8.9M	-19.44M	-31.26M	-45.54M	-37.73M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.17%	-0.47%	-0.55%	-0.26%	0.23%	-0.84%	-1.18%	-0.61%	-0.46%	0.17%
EBITDA+	-2.19M	-3.21M	-4.96M	-6.23M	-4.82M	-8.88M	-19.42M	-31.24M	-45.43M	-37.59M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.17%	-0.47%	-0.54%	-0.26%	0.23%	-0.84%	-1.19%	-0.61%	-0.45%	0.17%
D&A (Non-Cash Add-back)	1.8K	290	16.88K	18.83K	18.73K	19.46K	19.42K	20.51K	114.64K	147.89K
EBIT	-2.23M	-3.22M	-5.39M	-5.79M	-4.91M	-17.53M	-34.13M	-27.27M	-6.74M	-36.78M
Net Interest Income+	4.77K	6.42K	-4.37K	-19.41K	-36.2K	-96.2K	172.61K	1.2M	393.57K	115.09K
Interest Income	4.77K	6.42K	15.97K	12.06K	0	4.02K	173.86K	1.2M	393.57K	166.38K
Interest Expense	0	0	20.34K	31.47K	36.2K	100.22K	1.24K	0	0	51.29K
Other Income/Expense	-37.87K	-2.48K	-435.76K	434.77K	-104.51K	-8.73M	-14.69M	3.99M	38.81M	899.71K
Pretax Income+	-2.23M	-3.22M	-5.41M	-5.82M	-4.94M	-17.63M	-34.13M	-27.27M	-6.74M	-36.83M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	0.97%	0.99%
Net Income+	-2.23M	-3.22M	-5.41M	-5.82M	-4.94M	-17.63M	-34.13M	-27.27M	-6.55M	-36.5M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.36%	-0.44%	-0.68%	-0.08%	0.15%	-2.57%	-0.94%	0.2%	0.76%	-4.57%
Net Income (Continuing)	-2.23M	-3.22M	-5.41M	-5.82M	-4.94M	-17.63M	-34.13M	-27.27M	-6.74M	-36.83M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	-419.97K	-751.79K
EPS (Diluted)+	-1360.30	-1348.63	-1798.34	-1505.30	-1038.56	-585.01	-330.38	-261.86	-59.69	-86.25
EPS Growth %	0.4%	0.01%	-0.33%	0.16%	0.31%	0.44%	0.44%	0.21%	0.77%	-0.44%
EPS (Basic)	-1360.30	-1348.63	-1798.34	-1505.30	-1038.56	-585.01	-330.38	-261.86	-59.69	-86.25
Diluted Shares Outstanding	19.23K	22.65K	28.52K	38.64K	47.59K	301.31K	1.03M	1.04M	1.1M	423.11K
Basic Shares Outstanding	19.23K	22.65K	28.52K	38.64K	47.59K	301.31K	1.03M	1.04M	1.1M	423.11K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jul 2016	Jul 2017	Jul 2018	Jul 2019	Jul 2020	Jul 2021	Jul 2022	Jul 2023	Jul 2024	Jul 2025
Total Current Assets+	833.35K	1.63M	1.88M	168.53K	261.46K	72.23M	54.31M	35.99M	5.07M	27.4M
Cash & Short-Term Investments	820.6K	1.62M	1.75M	157.03K	21.25K	71.57M	52.63M	28.38M	1.2M	24.56M
Cash Only	131.58K	1.01M	720.26K	157.03K	21.25K	71.57M	52.63M	28.38M	1.2M	14.43M
Short-Term Investments	689.02K	601.76K	1.03M	0	0	0	0	0	0	10.14M
Accounts Receivable	2.67K	5.6K	14.56K	2.82K	22.52K	15.71K	30.91K	958.56K	1.9M	776.54K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	2.35K	1.91K	407.5K	276.12K	260.87K	306.96K	295.41K	287.23K	3.08M	2.37M
Property, Plant & Equipment	449	0	0	0	0	0	0	0	538.87K	408.1K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	274.73K	276.12K	260.87K	306.95K	295.4K	287.23K	277.36K	253.71K
Long-Term Investments	0	0	0	0	0	0	0	0	580.96K	720.84K
Other Non-Current Assets	1.9K	1.9K	132.76K	0	0	0	0	0	1.68M	986.51K
Total Assets+	835.7K	1.64M	2.28M	444.66K	522.33K	72.54M	54.6M	36.28M	8.15M	29.77M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.35%	0.96%	0.4%	-0.81%	0.17%	137.88%	-0.25%	-0.34%	-0.78%	2.65%
Total Current Liabilities+	48.59K	885.9K	1.34M	1.13M	3.96M	695.86K	1.21M	2.41M	10.36M	5.47M
Accounts Payable	0	0	0	0	0	267.59K	594.14K	1.5M	9.95M	4.51M
Days Payables Outstanding	-	-	-	-	-	5.02K	11.17K	26.71K	31.69K	11.14K
Short-Term Debt	0	0	1.12M	322.53K	249.8K	0	0	0	0	0
Deferred Revenue (Current)	0	506.91K	0	0	0	0	0	0	0	0
Other Current Liabilities	48.59K	379K	219.28K	810.79K	3.71M	0	0	0	0	954.58K
Current Ratio	17.15x	1.84x	1.40x	0.15x	0.07x	103.81x	45.00x	14.96x	0.49x	5.01x
Quick Ratio	17.15x	1.84x	1.40x	0.15x	0.07x	103.81x	45.00x	14.96x	0.49x	5.01x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	155.94K	37.26M	40.15M	38.92M	1.52M	464.27K
Long-Term Debt	0	0	0	0	0	32.48K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	-35.63K	37.23M	40.15M	38.92M	1.52M	464.27K
Total Liabilities	48.59K	885.9K	1.34M	1.13M	4.12M	37.96M	41.36M	41.32M	11.88M	5.93M
Total Debt+	0	0	1.12M	322.53K	249.8K	32.48K	0	0	0	0
Net Debt	-131.58K	-1.01M	400.4K	165.49K	228.55K	-71.54M	-52.63M	-28.38M	-1.2M	-14.43M
Debt / Equity	-	-	1.19x	-	-	0.00x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-244.39x	-198.70x	-133.64x	-88.81x	-15627.39x	-	-	-735.71x
Total Equity+	787.11K	750.23K	945.02K	-688.66K	-3.6M	34.58M	13.25M	-5.04M	-3.73M	23.83M
Equity Growth %	-0.32%	-0.05%	0.26%	-1.73%	-4.22%	10.61%	-0.62%	-1.38%	0.26%	7.39%
Book Value per Share	40.93	33.13	33.14	-17.82	-75.59	114.78	12.82	-4.84	-3.40	56.33
Total Shareholders' Equity	787.11K	750.23K	945.02K	-688.66K	-3.6M	34.58M	13.25M	-5.04M	-3.31M	24.58M
Common Stock	3.44M	5.3M	7.84M	11.11M	12.26M	68.45M	84.12M	92.94M	100.18M	139.88M
Retained Earnings	-4.27M	-6.68M	-9.74M	-14.75M	-18.17M	-36.42M	-77.4M	-107.71M	-118.61M	-153.65M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-23.23K	-57.91K	-80.98K	-101.18K	-138.68K	-173.32K	-177.86K	-185.22K	-192.52K	38.36M
Minority Interest	0	0	0	0	0	0	0	0	-419.97K	-751.79K

Cash Flow

	Jul 2016	Jul 2017	Jul 2018	Jul 2019	Jul 2020	Jul 2021	Jul 2022	Jul 2023	Jul 2024	Jul 2025
Cash from Operations+	-1.58M	-1.91M	-4.95M	-5.12M	-1.55M	-9.89M	-15.87M	-31.89M	-32.97M	-39.07M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.33%	-0.21%	-1.59%	-0.03%	0.7%	-5.36%	-0.61%	-1.01%	-0.03%	-0.19%
Net Income	-2.23M	-3.22M	-5.41M	-5.82M	-4.94M	-17.63M	-34.13M	-27.27M	-6.55M	-36.5M
Depreciation & Amortization	1.8K	290	16.88K	18.83K	18.73K	19.46K	19.42K	20.51K	114.64K	147.89K
Stock-Based Compensation	0	0	0	0	0	0	0	0	0	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	680.64K	271.74K	903.45K	-361.74K	88.77K	10.63M	18.73M	99.73K	-36.17M	-80.47K
Working Capital Changes	-28.99K	1.03M	-466.68K	1.04M	3.28M	-2.91M	-497.54K	-4.74M	9.64M	-2.65M
Change in Receivables	32.09K	-3.49K	-11.98K	15.59K	-24.19K	12.68K	-14.66K	7.02K	-1M	1.02M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	-5.39M
Cash from Investing+	208.98K	149.85K	-590.5K	1.35M	0	0	0	0	-931.67K	-10.61M
Capital Expenditures	0	0	0	0	0	0	0	0	-624.21K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	1.06M	2.89M	5.29M	3.01M	1.44M	82.92M	-4.76M	5.31M	6.04M	63.04M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	-29.98K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.58M	-1.91M	-4.95M	-5.12M	-1.55M	-9.89M	-15.87M	-31.89M	-33.59M	-39.07M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.33%	-0.21%	-1.59%	-0.03%	0.7%	-5.36%	-0.61%	-1.01%	-0.05%	-0.16%
FCF per Share	-82.07	-84.41	-173.70	-132.48	-32.67	-32.82	-15.37	-30.63	-30.62	-92.35
FCF Conversion (FCF/Net Income)	0.71x	0.59x	0.92x	0.88x	0.31x	0.56x	0.47x	1.17x	5.04x	1.07x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-229.34%	-418.57%	-637.98%	-4538.83%	-	-113.77%	-142.7%	-664.9%	-	-363.04%
Return on Invested Capital (ROIC)	-225.8%	-1232.55%	-689.81%	-1140.62%	-	-	-	-	-	-1263.21%
Debt / Equity	-	-	1.19x	-	-	0.00x	-	-	-	-
Interest Coverage	-	-	-244.39x	-198.70x	-133.64x	-88.81x	-15627.39x	-	-	-735.71x
FCF Conversion	0.71x	0.59x	0.92x	0.88x	0.31x	0.56x	0.47x	1.17x	5.04x	1.07x

Frequently Asked Questions

Growth & Financials

BriaCell Therapeutics Corp. (BCTX) reported $0.2M in revenue for fiscal year 2025.

BriaCell Therapeutics Corp. (BCTX) grew revenue by 0.0% over the past year. Growth has been modest.

BriaCell Therapeutics Corp. (BCTX) reported a net loss of $37.0M for fiscal year 2025.

Dividend & Returns

BriaCell Therapeutics Corp. (BCTX) has a return on equity (ROE) of -363.0%. Negative ROE indicates the company is unprofitable.

BriaCell Therapeutics Corp. (BCTX) had negative free cash flow of $40.6M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

BriaCell Therapeutics Corp. (BCTX) 10-Year Financial Performance & Capital Metrics

BCTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$38M +17.3%
Net Income -$36M -457.4%
EPS (Diluted) -86.25 -44.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -363.04%
ROIC -1263.21%
Debt/Equity -
Interest Coverage -735.71

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 61.4% through buybacks
✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-64.28%

EPS CAGR

10Y-

5Y-

3Y-

TTM62.75%

ROCE

10Y Avg-762.92%

5Y Avg-151.59%

3Y Avg-233.64%

Latest-341.62%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Jul 2016	Jul 2017	Jul 2018	Jul 2019	Jul 2020	Jul 2021	Jul 2022	Jul 2023	Jul 2024	Jul 2025
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	1.8K	290	16.88K	18.83K	18.73K	19.46K	19.42K	20.51K	114.64K	147.89K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-1.8K	-289	-16.88K	-18.83K	-18.73K	-19.46K	-19.42K	-20.51K	-114.64K	-147.89K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-2.19%	0.84%	-57.4%	-0.12%	0.01%	-0.04%	0%	-0.06%	-4.59%	-0.29%
Operating Expenses+	2.19M	3.21M	4.96M	6.23M	4.82M	8.88M	19.42M	31.24M	45.43M	37.59M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	1.24M	1.09M	1.85M	1.29M	1.84M	6.3M	9.22M	10.64M	8.29M	5.93M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	952.15K	2.12M	3.11M	4.94M	2.98M	2.58M	10.2M	20.6M	37.14M	29.5M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	2.15M
Operating Income+	-2.19M	-3.21M	-4.97M	-6.25M	-4.84M	-8.9M	-19.44M	-31.26M	-45.54M	-37.73M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.17%	-0.47%	-0.55%	-0.26%	0.23%	-0.84%	-1.18%	-0.61%	-0.46%	0.17%
EBITDA+	-2.19M	-3.21M	-4.96M	-6.23M	-4.82M	-8.88M	-19.42M	-31.24M	-45.43M	-37.59M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.17%	-0.47%	-0.54%	-0.26%	0.23%	-0.84%	-1.19%	-0.61%	-0.45%	0.17%
D&A (Non-Cash Add-back)	1.8K	290	16.88K	18.83K	18.73K	19.46K	19.42K	20.51K	114.64K	147.89K
EBIT	-2.23M	-3.22M	-5.39M	-5.79M	-4.91M	-17.53M	-34.13M	-27.27M	-6.74M	-36.78M
Net Interest Income+	4.77K	6.42K	-4.37K	-19.41K	-36.2K	-96.2K	172.61K	1.2M	393.57K	115.09K
Interest Income	4.77K	6.42K	15.97K	12.06K	0	4.02K	173.86K	1.2M	393.57K	166.38K
Interest Expense	0	0	20.34K	31.47K	36.2K	100.22K	1.24K	0	0	51.29K
Other Income/Expense	-37.87K	-2.48K	-435.76K	434.77K	-104.51K	-8.73M	-14.69M	3.99M	38.81M	899.71K
Pretax Income+	-2.23M	-3.22M	-5.41M	-5.82M	-4.94M	-17.63M	-34.13M	-27.27M	-6.74M	-36.83M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	0.97%	0.99%
Net Income+	-2.23M	-3.22M	-5.41M	-5.82M	-4.94M	-17.63M	-34.13M	-27.27M	-6.55M	-36.5M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.36%	-0.44%	-0.68%	-0.08%	0.15%	-2.57%	-0.94%	0.2%	0.76%	-4.57%
Net Income (Continuing)	-2.23M	-3.22M	-5.41M	-5.82M	-4.94M	-17.63M	-34.13M	-27.27M	-6.74M	-36.83M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	-419.97K	-751.79K
EPS (Diluted)+	-1360.30	-1348.63	-1798.34	-1505.30	-1038.56	-585.01	-330.38	-261.86	-59.69	-86.25
EPS Growth %	0.4%	0.01%	-0.33%	0.16%	0.31%	0.44%	0.44%	0.21%	0.77%	-0.44%
EPS (Basic)	-1360.30	-1348.63	-1798.34	-1505.30	-1038.56	-585.01	-330.38	-261.86	-59.69	-86.25
Diluted Shares Outstanding	19.23K	22.65K	28.52K	38.64K	47.59K	301.31K	1.03M	1.04M	1.1M	423.11K
Basic Shares Outstanding	19.23K	22.65K	28.52K	38.64K	47.59K	301.31K	1.03M	1.04M	1.1M	423.11K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jul 2016	Jul 2017	Jul 2018	Jul 2019	Jul 2020	Jul 2021	Jul 2022	Jul 2023	Jul 2024	Jul 2025
Total Current Assets+	833.35K	1.63M	1.88M	168.53K	261.46K	72.23M	54.31M	35.99M	5.07M	27.4M
Cash & Short-Term Investments	820.6K	1.62M	1.75M	157.03K	21.25K	71.57M	52.63M	28.38M	1.2M	24.56M
Cash Only	131.58K	1.01M	720.26K	157.03K	21.25K	71.57M	52.63M	28.38M	1.2M	14.43M
Short-Term Investments	689.02K	601.76K	1.03M	0	0	0	0	0	0	10.14M
Accounts Receivable	2.67K	5.6K	14.56K	2.82K	22.52K	15.71K	30.91K	958.56K	1.9M	776.54K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	2.35K	1.91K	407.5K	276.12K	260.87K	306.96K	295.41K	287.23K	3.08M	2.37M
Property, Plant & Equipment	449	0	0	0	0	0	0	0	538.87K	408.1K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	274.73K	276.12K	260.87K	306.95K	295.4K	287.23K	277.36K	253.71K
Long-Term Investments	0	0	0	0	0	0	0	0	580.96K	720.84K
Other Non-Current Assets	1.9K	1.9K	132.76K	0	0	0	0	0	1.68M	986.51K
Total Assets+	835.7K	1.64M	2.28M	444.66K	522.33K	72.54M	54.6M	36.28M	8.15M	29.77M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.35%	0.96%	0.4%	-0.81%	0.17%	137.88%	-0.25%	-0.34%	-0.78%	2.65%
Total Current Liabilities+	48.59K	885.9K	1.34M	1.13M	3.96M	695.86K	1.21M	2.41M	10.36M	5.47M
Accounts Payable	0	0	0	0	0	267.59K	594.14K	1.5M	9.95M	4.51M
Days Payables Outstanding	-	-	-	-	-	5.02K	11.17K	26.71K	31.69K	11.14K
Short-Term Debt	0	0	1.12M	322.53K	249.8K	0	0	0	0	0
Deferred Revenue (Current)	0	506.91K	0	0	0	0	0	0	0	0
Other Current Liabilities	48.59K	379K	219.28K	810.79K	3.71M	0	0	0	0	954.58K
Current Ratio	17.15x	1.84x	1.40x	0.15x	0.07x	103.81x	45.00x	14.96x	0.49x	5.01x
Quick Ratio	17.15x	1.84x	1.40x	0.15x	0.07x	103.81x	45.00x	14.96x	0.49x	5.01x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	155.94K	37.26M	40.15M	38.92M	1.52M	464.27K
Long-Term Debt	0	0	0	0	0	32.48K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	-35.63K	37.23M	40.15M	38.92M	1.52M	464.27K
Total Liabilities	48.59K	885.9K	1.34M	1.13M	4.12M	37.96M	41.36M	41.32M	11.88M	5.93M
Total Debt+	0	0	1.12M	322.53K	249.8K	32.48K	0	0	0	0
Net Debt	-131.58K	-1.01M	400.4K	165.49K	228.55K	-71.54M	-52.63M	-28.38M	-1.2M	-14.43M
Debt / Equity	-	-	1.19x	-	-	0.00x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-244.39x	-198.70x	-133.64x	-88.81x	-15627.39x	-	-	-735.71x
Total Equity+	787.11K	750.23K	945.02K	-688.66K	-3.6M	34.58M	13.25M	-5.04M	-3.73M	23.83M
Equity Growth %	-0.32%	-0.05%	0.26%	-1.73%	-4.22%	10.61%	-0.62%	-1.38%	0.26%	7.39%
Book Value per Share	40.93	33.13	33.14	-17.82	-75.59	114.78	12.82	-4.84	-3.40	56.33
Total Shareholders' Equity	787.11K	750.23K	945.02K	-688.66K	-3.6M	34.58M	13.25M	-5.04M	-3.31M	24.58M
Common Stock	3.44M	5.3M	7.84M	11.11M	12.26M	68.45M	84.12M	92.94M	100.18M	139.88M
Retained Earnings	-4.27M	-6.68M	-9.74M	-14.75M	-18.17M	-36.42M	-77.4M	-107.71M	-118.61M	-153.65M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-23.23K	-57.91K	-80.98K	-101.18K	-138.68K	-173.32K	-177.86K	-185.22K	-192.52K	38.36M
Minority Interest	0	0	0	0	0	0	0	0	-419.97K	-751.79K

Cash Flow

	Jul 2016	Jul 2017	Jul 2018	Jul 2019	Jul 2020	Jul 2021	Jul 2022	Jul 2023	Jul 2024	Jul 2025
Cash from Operations+	-1.58M	-1.91M	-4.95M	-5.12M	-1.55M	-9.89M	-15.87M	-31.89M	-32.97M	-39.07M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.33%	-0.21%	-1.59%	-0.03%	0.7%	-5.36%	-0.61%	-1.01%	-0.03%	-0.19%
Net Income	-2.23M	-3.22M	-5.41M	-5.82M	-4.94M	-17.63M	-34.13M	-27.27M	-6.55M	-36.5M
Depreciation & Amortization	1.8K	290	16.88K	18.83K	18.73K	19.46K	19.42K	20.51K	114.64K	147.89K
Stock-Based Compensation	0	0	0	0	0	0	0	0	0	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	680.64K	271.74K	903.45K	-361.74K	88.77K	10.63M	18.73M	99.73K	-36.17M	-80.47K
Working Capital Changes	-28.99K	1.03M	-466.68K	1.04M	3.28M	-2.91M	-497.54K	-4.74M	9.64M	-2.65M
Change in Receivables	32.09K	-3.49K	-11.98K	15.59K	-24.19K	12.68K	-14.66K	7.02K	-1M	1.02M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	-5.39M
Cash from Investing+	208.98K	149.85K	-590.5K	1.35M	0	0	0	0	-931.67K	-10.61M
Capital Expenditures	0	0	0	0	0	0	0	0	-624.21K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	1.06M	2.89M	5.29M	3.01M	1.44M	82.92M	-4.76M	5.31M	6.04M	63.04M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	-29.98K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.58M	-1.91M	-4.95M	-5.12M	-1.55M	-9.89M	-15.87M	-31.89M	-33.59M	-39.07M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.33%	-0.21%	-1.59%	-0.03%	0.7%	-5.36%	-0.61%	-1.01%	-0.05%	-0.16%
FCF per Share	-82.07	-84.41	-173.70	-132.48	-32.67	-32.82	-15.37	-30.63	-30.62	-92.35
FCF Conversion (FCF/Net Income)	0.71x	0.59x	0.92x	0.88x	0.31x	0.56x	0.47x	1.17x	5.04x	1.07x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-229.34%	-418.57%	-637.98%	-4538.83%	-	-113.77%	-142.7%	-664.9%	-	-363.04%
Return on Invested Capital (ROIC)	-225.8%	-1232.55%	-689.81%	-1140.62%	-	-	-	-	-	-1263.21%
Debt / Equity	-	-	1.19x	-	-	0.00x	-	-	-	-
Interest Coverage	-	-	-244.39x	-198.70x	-133.64x	-88.81x	-15627.39x	-	-	-735.71x
FCF Conversion	0.71x	0.59x	0.92x	0.88x	0.31x	0.56x	0.47x	1.17x	5.04x	1.07x

Frequently Asked Questions

Growth & Financials

BriaCell Therapeutics Corp. (BCTX) reported $0.2M in revenue for fiscal year 2025.

BriaCell Therapeutics Corp. (BCTX) grew revenue by 0.0% over the past year. Growth has been modest.

BriaCell Therapeutics Corp. (BCTX) reported a net loss of $37.0M for fiscal year 2025.

Dividend & Returns

BriaCell Therapeutics Corp. (BCTX) has a return on equity (ROE) of -363.0%. Negative ROE indicates the company is unprofitable.

BriaCell Therapeutics Corp. (BCTX) had negative free cash flow of $40.6M in fiscal year 2025, likely due to heavy capital investments.